What's hard to know about the MANF mystery is how much of it's potential we'll actually be able to capitalize on? I think the indications for the "Eye Franchise" we have within our grasp. I can see that happening. (Retinitis, Glaucoma, Macular Degeneration, Eye damage due to diabetes/wolframs, etc)

But everything else seems so far away, and it is unclear which MANF articles reporting on positive preclinical research will end up falling within our patent rights...and actually benefiting us.

I suspect Parkinsons is one of our strongest fits, after the Eye Franchise. Ischemic Heart disease is also right up there. It would be interesting for someone with more of a science background to separate those indications that are probably most ideal for recombinant MANF, from those which are more apt to be suited for small molecules targeting endogenous MANF production in the body?